CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis

Laine, Anni

2021-08

Laine , A , Nagelli , S G , Farrington , C , Butt , U , Cvrljevic , A N , Vainonen , J P , Feringa , F M , Gronroos , T J , Gautam , P , Khan , S , Sihto , H , Qiao , X , Pavic , K , Connolly , D C , Kronqvist , P , Elo , L L , Maurer , J , Wennerberg , K , Medema , R H , Joensuu , H , Peuhu , E , de Visser , K , Narla , G & Westermarck , J 2021 , ' CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis ' , Cancer Research , vol. 81 , no. 16 , pp. 4319-4331 . https://doi.org/10.1158/0008-5472.CAN-20-3651

http://hdl.handle.net/10138/335008
https://doi.org/10.1158/0008-5472.CAN-20-3651

acceptedVersion

CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis

Anni Laine[1,2]*, Srikar G. Nagelli[1,3]*, Caroline Farrington[4,5], Umar Butt[1,3], Anna N. Cvrljevic[1], Julia P. Vainonen[1], Femke M. Feringa[6#], Tove J. Grönroos[7,8], Prson Gautam[9], Sofia Khan[1], Harri Sihto[10], Xi Qiao[1], Karolina Pavic[1], Denise C. Connolly[11], Pauliina Kronqvist[3], Laura L. Elo[1,3], Jochen Maurer[12], Krister Wennerberg[9], Rene H. Medema[6], Heikki Joensuu[10], Emilia Peuhu[1,3], Karin de Visser[2,13], Goutham Narla[4,5], and Jukka Westermarck[1,3§]

[1]Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
[2]Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
[3]Institute of Biomedicine, University of Turku, Turku, Finland
[4]Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48105, USA.
[5]Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA.
[6]Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
[7]Turku PET Centre, University of Turku, Turku, Finland
[8]Department of Oncology and Radiotherapy, Turku University Hospital,Turku, Finland
[9]Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
[10]Department of Pathology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
[11]Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA
[12]Department of Obstetrics and Gynecology, University Hospital Aachen (UKA), 52074 Aachen, Germany
[13]Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands

*These authors contributed equally
[#]Current address: Department of Molecular and Cellular Neurobiology, Faculty of Science, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 1081HV, Amsterdam, The Netherlands

Running title: CIP2A drives basal-like breast cancers via TopBP1 and MYC

§ **Corresponding author:** Jukka Westermarck, Turku Bioscience Centre, University of Turku, Tykistökatu 6B, 20540 Turku, Finland, tel: +358-294502880, fax: +358-294505040, e-mail: jukwes@utu.fi

Conflicts of interest: The authors declare no potential conflicts of interest

Total word count: 7495, 7 figures

Abstract

Basal-like breast cancers (BLBC) are characterized by defects in homologous recombination (HR), deficient mitotic checkpoint, and high proliferation activity. Here, we discover CIP2A as a candidate driver of BLBC. CIP2A was essential for DNA-damage-induced initiation of mouse BLBC-like mammary tumors and for survival of homologous recombination defective (HRD) BLBC cells. CIP2A was dispensable for normal mammary gland development and for unperturbed mitosis, but selectively essential for mitotic progression of DNA-damaged cells. A direct interaction between CIP2A and a DNA repair scaffold protein TopBP1 was identified and CIP2A inhibition resulted in enhanced DNA damage-induced TopBP1 and RAD51 recruitment to chromatin in mammary epithelial cells. In addition to its role in tumor initiation, and survival of BRCA-deficient cells, CIP2A also drove proliferative MYC and E2F1 signaling in basal-like triple negative breast cancer (BL-TNBC) cells. Clinically, high CIP2A expression was associated with poor patient prognosis in BL-TNBCs but not in other breast cancer subtypes. Small molecule reactivators of PP2A (SMAPs) inhibited CIP2A transcription, phenocopied the CIP2A-deficient DNA damage response (DDR), and inhibit growth of patient-derived BLBC xenograft. In summary, these results demonstrate that CIP2A directly interacts with TopBP1 and coordinates DNA-damage induced mitotic checkpoint and proliferation, thereby driving BLBC initiation and progression. SMAPs could serve as a surrogate therapeutic strategy to inhibit the oncogenic activity of CIP2A in BLBCs.

Significance: These results identify CIP2A as a non-genetic driver and therapeutic target in basal-like breast cancer that regulates DNA-damage-induced G2/M checkpoint and proliferative signaling.

Keywords: ATR, RHNO1, Nibrin, Double stranded DNA break, DT-061

Introduction

One of the most aggressive and clinically challenging breast cancer subtypes is the basal-like breast cancer (BLBC)(1-3). Based on transcriptional signatures of the breast cancer subtypes (4), the hallmarks of BLBCs are high proliferation activity, G2/M checkpoint dysregulation, ATR/BRCA pathway activity, and high DNA replication. Additionally, molecular characteristics of BLBCs include high genetic instability, BRCA mutations, TP53 inactivation, and dysregulation of EGFR (1-4). About 75% of BLBCs belong to the triple-negative breast cancer subtype (BL-TNBCs), devoid of ER, PR and HER2 (1). In addition to their frequently aggressive clinical appearance, the lack of these targetable receptors makes BLBCs therapeutically very challenging. Despite the near saturated genetic knowledge of breast cancer, like some other subtypes as well, no clear genetic oncogenic drivers have been identified for the BLBCs (1,3).

Among the breast cancer subtypes, BLBCs have the highest mutational burden as a result of acquisition of BRCA mutations, or other defects in the homologous recombination (HR) pathways (1-4). Normal HR proficient cells respond to double stranded DNA breaks (DSB) by activating the G2/M cell cycle checkpoint resulting in mitotic arrest (5). To allow mitotic progression under DNA damaging conditions, transformed cells instead have developed strategy to dampen G2/M checkpoint signaling (5,6). Based on the high mutational burden observed in BLBC, it could be hypothesized that a potential BLBC driver mechanism has the ability to coordinately dampen the DNA-damage induced G2/M checkpoint, and to support high proliferation activity in premalignant mammary epithelial cells. One of the DDR proteins involved in G2/M checkpoint signaling is DNA Topoisomerase II binding protein 1 (TopBP1)(7), which is a scaffold protein that interacts with the checkpoint kinase

ATR (8). In the presence of DSBs, TopBP1 promotes RAD51 chromatin loading resulting in G2/M arrest (9-12). RAD51 foci formation has been associated in BLBCs as a marker of BRCA deficiency and HR impairment (4,13). These features make TopBP1-mediated RAD51 regulation a candidate G2/M checkpoint mechanism in BLBC (5,7,10).

Recently the serine/threonine phosphatase PP2A has gained attention as a druggable tumor suppressor (14-16). Of specific relevance to this work, is the role of serine/threonine phosphatases in the DNA damage response at chromatin (6), which could link them to cancer types with homologous recombination defects, and high mutational burden, such as BLBCs. PP2A is inhibited in most cancers by non-genetic mechanisms including high expression of endogenous inhibitor proteins such as CIP2A, PME-1 or SET, or changes in carboxymethylation to the C terminal tail of the catalytic domain (15,17). *CIP2A* is expressed at low levels in normal mammary gland tissue (18). However, *CIP2A* transcription is induced by *TP53* mutation via increased E2F1 activity (18,19), and by EGFR pathway activation (20,21), features closely linked to BLBC (1). However, it is currently unclear what role CIP2A plays in BLBC initiation, or progression. Notably, understanding of CIP2A-related cancer initiation mechanisms is also therapeutically relevant due to the recent development of small molecule activators of the CIP2A-inhibited PP2A-B56 heterotrimer that demonstrate potent antitumor activities (14,16).

In this study, we provide the first evidence for an essential role for CIP2A in tumor initiation in cancer. Specifically, we demonstrate by using both chemical and transgenic tumor models that CIP2A is essential for the initiation of mouse BLBC tumors, but not for the initiation of skin, ovarian, lung or stomach tumors. Furthermore, among transformed breast cancer cell types, CIP2A is essential for survival of BRCA/TP53-mutant BLBC cells.

Mechanistically, the role for CIP2A in driving BLBC initiation and progression can be explained by its capacity to coordinately regulate key BLBC hallmarks; specifically the G2/M checkpoint and cellular proliferation. Molecularly we discover direct CIP2A interaction with TopBP1 and provide evidence for CIP2A-mediated inhibition of both TopBP1 and RAD51 recruitment to chromatin upon DNA-damage in premalignant mammary epithelial cells. CIP2A also promotes pro-proliferative MYC and E2F1 activities in BLBC cells. Finally, we discover that small molecules shown previously to activate PP2A (16,22), transcriptionally inhibit *CIP2A* expression, and serve as candidate therapeutics for CIP2A-positive BLBCs.

Materials and Methods

Mouse experiments

All animal work protocols were approved either by the Project Authorisation Board of the Regional State Administrative Agency for Southern Finland, the Animal Ethics Committee of the Netherlands Cancer Institute or the Institutional Animal Care and Use Committee at the Case Western Reserve University, which is certified by the American Association of Accreditation for Laboratory Animal Care under protocol # 2013-0132.

For DMBA-induced tumors in *WT* and *Cip2a-/-* female mice, several independent cohorts of the mice were administered with 1mg of DMBA dissolved in 200µl of corn oil by oral gavage once a week for 6 weeks starting at 12-14 weeks of age as previously described (23). The mice were monitored twice a week for tumor formation until morbidity. Mice were sacrificed upon tumor burden and/or when they showed general signs of illness. For DMBA-induced mutation load and *Cip2a* mRNA expression in *WT* and *Cip2a-/-* premalignant mammary gland tissues, the mice were sacrificed 2 weeks after the last DMBA treatment. DMBA/TPA protocol for skin tumorigenesis and experiments with *Cip2a-/-* mice crossed with an ovarian cancer mouse model *TgMISIIR-Tag* are described in supplementary materials and methods. Tissue samples collected for extraction of RNA and genomic DNA were snap frozen into liquid nitrogen. Tissue samples for histochemical and for immunohistochemical analysis were fixed in formalin.

Mouse tumor cell lines were generated from spontaneous mammary tumors of following breast cancer mouse models: *K14Cre; Brca1*$^{F/F}$*; Trp53*$^{F/F}$(*KB1P*) (24), *K14Cre; Cdh1*$^{F/F}$*; Trp53*$^{F/F}$(*KEP*) (25) and *Wap-cre; Cdh1*$^{F/F}$*; Akt1*^{E17K}(*WEA*) (26). Tumor cell lines were

generated by collecting tumors in cold PBS and minced by chopping with scalpels. Aggregates were plated out. *KEP* and *WEA* tumor cell line cultures were incubated at 37°C with 5% CO_2 and 20% O_2. *KB1P* cell lines were incubated at 37°C with 5% CO_2 and 3% O_2. Homogenous epithelial cell morphology was obtained after cultures were passaged 2-3 times. Used cell culture media are described in Table S1.

Analysis of human breast cancer patient sample cohorts

FinHer study (HUCH 426/E6/00) was approved by an ethics committee of the Helsinki University Central Hospital (Helsinki, Finland). Study participants provided written informed consent before study entry. The study was conducted in accordance of the Declaration of Helsinki. The role of *CIP2A* in disease-free survival of breast cancer patients in the GSE21653 cohort was analyzed by using an online platform 'R2: Genomics Analysis and Visualization Platform' (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). More detailed description of analysis of both cohorts can be found from supplemental data.

Cell culture and transfections

All the commercial cell lines used in this paper were purchased from American Type Culture Collection (ATCC) or Leibniz Institute's German Collection of Microorganisms and Cell Cultures (DSMZ). All the cells in culture were negative on periodically testing for mycoplasma using Mycoplasma Detection Kit (Roche). All the human and mouse cells, their culture conditions and supplements used for cell culture are listed in Table S1. Breast cancer stem-like cells (BCSCs) were isolated from TNBC patients who received standard chemotherapy and cultured as described previously (27).

Antibodies, RNAs, primers, DNA constructs and drugs.

Antibodies (along with dilutions for each application), plasmids and sequences of siRNAs, gRNAs and primers used are listed in Table S2. All chemical inhibitors and drugs used are listed in the Table S3.

Mitotic index experiments

Mitotic index experiments were conducted by modifying previously published protocol described in (7). Briefly, MCF10A cells were transfected with indicated siRNAs for 24 hours, following which they were seeded into ibidi 8 well μ slides (ibiTreat #80826) for 24 hours. Cells were irradiated with 10Gy radiation followed by Nocodazole block (100ng/ml), one hour after IR for 18 hours. After the indicated time points, cells were stained for phospho-Histone H3 (Ser10) using similar immunofluorescence protocols as mentioned above. Images were taken on Zeiss Axiovert or EVOS fl Microscope with 10X objective and quantified using ImageJ software (RRID:SCR_003070). Experiment was repeated 3 times.

Results

Cip2a is selectively required for initiation of DMBA-induced mammary tumors in mice

To address whether CIP2A is truly essential for the initiation of cancer *in vivo,* we challenged several independent cohorts of the previously described *Cip2a-/-* mice (19,28) with a chemical carcinogenesis protocol consisting of six consecutive doses of the genotoxic agent 7,12-dimethylbenz[a]anthracene (DMBA) (Fig. 1A). Similar to other polyaromatic hydrocarbons, DMBA forms covalent DNA adducts, and induces a DNA damage response (DDR) including activation of ɣH2AX, ATR, and RAD51 (29). Oral exposure of mice to DMBA induces mouse BLBCs (23), but also several other cancers, allowing us to assess the relative importance of *Cip2a* to tumor development across different cancer types. As compared to a model combining DMBA and medroxyprogesterone acetate (MPA), the DMBA-only mammary tumors are initiated with much longer latency (23). Importantly, the tumor initiating cell type of mammary tumors induced by DMBA-only is basaloid cells, and molecularly these tumors faithfully resemble human BLBCs (23).

As expected (29), DMBA treatment induced a significant increase in the mutational load in non-tumorigenic mammary gland tissue as soon as only 2 weeks after the last DMBA dose; however the mutational load (Fig. 1 B and Table S4), or overall survival (Fig. S1A) was not associated with the *Cip2a* genotype. When assessed by palpation, external observation, and by tissue pathology analysis upon autopsy of the mice with any symptoms of reduced well-being, tumors in five different tissue types were observed in the DMBA-treated mice (Fig. 1C). Notably, while incidence of tumors in ovary, lung, skin or

stomach were not altered in *Cip2a-/-* mice, mammary tumors showed almost absolute dependence on *Cip2a* for tumor initiation (Fig. 1C, D and S1B).

To control for the possibility that lack of genotype dependence of other cancer types on *Cip2a* was a result of leakage of the genetrap cassette used for *Cip2a* gene silencing (28), we confirmed the absence of CIP2A protein expression in ovarian cancer tissues from *Cip2a-/-* mice (Fig. S1C). We further confirmed that *Cip2a* was dispensable for skin and ovarian tumorigenesis by independent *in vivo* models. To this end, we crossed *Cip2a-/-* mice with the MISIIR-Tag mouse model producing tumors resembling high grade ovarian cancer (30), and did not observe any notable difference in ovarian tumorigenesis between *Cip2a* wild-type (*WT*) or *Cip2a-/-* mice by PET/CT-imaging or by visual inspection after autopsy (Fig. S1D,E). For the skin tumorigenesis model, we used a classical DMBA/TPA two-stage skin tumorigenesis protocol and again did not observe any differences in skin tumor initiation between the *Cip2a* genotypes (Fig. S1F).

Combined, these results in multiple independent in vivo models strongly suggest that CIP2A is required for the propagation of DNA-damaged mammary basaloid epithelial cells. To validate that this is a cell intrinsic property of CIP2A, we tested the impact of CIP2A silencing on mitotic progression of MCF-10A basal like immortalized mammary epithelial cells treated with ionizing radiation (IR). Notably, whereas inhibition of checkpoint kinase CHK1 abrogated the G2/M checkpoint and CIP2A silencing did not impact mitotic progression of untreated MCF-10A cells, CIP2A was found to be indispensable for G2/M progression in IR-treated MCF10A cells (Fig. 1E and S1G). To provide independent validation to these results, we surveyed results from a genetic screen in HAP1 cells (31) (see Fig. S1H for technical description). Directly supportive of the role for CIP2A in

allowing cell propagation under DNA damage, CIP2A was the only tested PP2A inhibitor protein that was essential under repeated low-dose irradiation (Fig. 1F).

These results establish essentiality for *Cip2a* for the initiation of DNA-damage induced mammary tumors previously confirmed to faithfully represent mouse BLBCs (23). As such the results represent the first evidence for a critical role for CIP2A in tumor initiation.

***Cip2a* is induced by DMBA in premalignant mammary gland tissue and drives initiation of mouse BLBC-like tumors**

A key criterion for a cancer driver candidate involved in tumor initiation, is expression in premalignant tissue prior tumorigenesis. Consistent with negligible CIP2A protein expression in normal human mammary glands (18), *Cip2a* mRNA was expressed at a very low level in *WT* mouse mammary glands (Fig. 2A). Importantly, non-tumorous *WT* mammary glands sampled 2 weeks after the last dose of DMBA (Fig. 1A) displayed significantly increased *Cip2a* mRNA expression (Fig. 2A). In line with a suggested role as a disease driver, *Cip2a* mRNA expression was induced significantly more in mammary tumors from DMBA-treated *WT* mice (Fig. 2A). However, as mammary tumors were induced in only some of the mammary glands in each of the DMBA-treated WT mice, we conclude that *Cip2a* expression is essential, but not sufficient alone to induce tumorigenesis.

Based upon the molecular characterization of the mammary tumors from DMBA-treated *WT* mice, the majority of the characterized tumors had BLBC or BL-TNBC phenotypes

(Fig. 2B,C and S2A). This is consistent with a previous report demonstrating that the tumor initiating cells from this DMBA model are of basaloid origin (23). The small number of estrogen receptor (ER) positive tumors observed is consistent with TCGA data that about 10% of human BLBCs are ER positive. Furthermore, although use of different DMBA *in vivo* protocol was recently shown to result in ER positive tumors (32), it was demonstrated by using the DMBA protocol used in our study that serial transplantation of ER positive tumors yielded ER negative secondary tumors, suggesting that ER expression was not a driver mechanism in these tumors (23). To study the impact of *Cip2a* on DMBA-induced mammary gland gene expression profiles, we performed RNA-sequencing analysis of non-tumorigenic mammary glands from mice housed for more than 4 months after the last dose of DMBA. Fully consistent with basaloid and HRD phenotype, *Cip2a* was found to control G2/M checkpoint, and proliferative signaling via the MYC and E2F1 pathways (Fig. 2D). The tumors in *WT* mice were also highly proliferative based on Ki67 staining, and displayed both CIP2A and MYC protein overexpression potentially indicative of their known feed-forward regulatory loop (33)(Fig. 2B). Evaluating the CIP2A positivity in DMBA-treated pre-tumorigenic mammary gland duct epithelial cells and from mammary tumors in *WT* mice, revealed predominantly cytoplasmic, but also nuclear CIP2A protein expression (Fig.S2B). This pattern is consistent with previous analysis indicating that there is a small pool of nuclear CIP2A in propagating cells (34), and indicate a potential function for nuclear CIP2A in early mammary tumorigenesis. Notably, the lack of predominantly BLBC tumors in *Cip2a-/-* mice was not related to any genotype-associated alterations in the basal and luminal epithelial cell ratio in the mammary gland (Fig. S2C-F). Furthermore, we did not observe any notable differences in the mammary gland development and branching morphogenesis between *WT* and *Cip2a-/-* mice (Fig. S2G).

Collectively, these results demonstrate that although *Cip2a* is dispensable for normal mouse mammary development, DMBA-elicited induction of *Cip2a* mRNA expression is required for initiation of mouse BLBC-like tumors.

Co-dependence analysis reveals a functional association between CIP2A, TopBP1 and G2/M checkpoint regulation

Although our results strongly indicate that the previously reported CIP2A-MYC feed-forward loop (33,35,36) is highly relevant for proliferation in DMBA-induced BLBCs (Fig. 2B and S2A), MYC regulation is unlikely to explain either the newly discovered role for CIP2A in G2/M checkpoint regulation (Fig. 1E,F and S2A), or its essentiality for *in vivo* propagation of DNA-damaged mammary epithelial cells (Fig. 1C,D and S2G). Furthermore, as TPA/DMBA-induced skin tumorigenesis is dependent on MYC (37), but totally independent of CIP2A (Fig. S1F), we hypothesized that CIP2A is involved in the regulation of a yet uncharacterized MYC-independent, but HRD-related mechanism. To identify such mechanism in an unbiased manner, we surveyed a CRISPR/Cas9-based dropout screen repository from DepMap (Avana 2020 Q1; https://depmap.org), to identify genes that are most significantly similar in their essentiality with *CIP2A*.

Remarkably, across 739 human cancer cell lines all the top 10 co-dependent genes with *CIP2A* (i.e. functionally most similar to CIP2A) were DDR genes (Fig. 3A). Notably, out of these top ten *CIP2A*-associated DDR factors, *CIP2A* was at the genome-wide level the most significantly similar gene for *RHNO1, TOPBP1*, *POLQ, NBN* and *PARP1* (Fig. 3A). In the case of *TOPBP1*, the co-dependency with *CIP2A* was greater than with *ATR* (Fig. 3B), which is the bona-fide TopBP1 DDR effector (7,8). On the other hand, strongly supporting

the selectivity of CIP2A´s association with DDR mechanisms, and arguing against MYC being the sole effector of CIP2A in tumorigenesis, there was no overlapping genes found among the top ten co-dependent genes between *CIP2A* and *MYC* (Fig. 3A and S3A).

When analyzed for functional protein association networks by STRING database (https://string-db.org), the top CIP2A-associated proteins (Fig. 3A) formed a tight protein network (Fig. 3C), that was functionally linked with HRD-associated processes such as "G2/M DNA damage checkpoint", "Homology directed Repair", and "Processing of DNA double-strand break ends" (Fig. 3D). Interestingly, in a recent PP2A-related phosphoproteome survey (38), CIP2A was found to prevent the dephosphorylation of Nibrin (NBN), which was one of the TopBP1 protein network members (Fig. 3C). NBN is known to co-operate with TopBP1 in ATR activation, and dephosphorylation of serine 432 of NBN, as observed in CIP2A depleted cells (Fig. S3B)(38), impairing cell survival under IR (39). CIP2A was also recently found to be a NBN co-dependent gene in PARP inhibitor treated cells (40).

Additional evidence for the intertwining of CIP2A with the TopBP1 complex was obtained by mRNA co-expression analysis across 1156 cell lines from the Broad institute Cancer Cell line Encyclopedia. Of the *CIP2A* co-dependent genes (Fig. 3A), *TOPBP1* and *POLQ* were also among the 25 most significantly co-expressed genes with CIP2A (Fig. 3E and Fig. S4A). Both *TOPBP1* and *POLQ* showed very significant co-expression with *CIP2A* also when only the BLBC cell lines were surveyed (Fig. S4B). The DepMap co-dependence data was also utilized to understand the interesting difference in CIP2A dependence in the initiation of mammary and ovarian cancers (Fig. 1). To this end, we analyzed in a pair-wise fashion the correlation between dependence on either *CIP2A*, or

one of the functionally most similar genes *RHNO1, TOPBP1*, *POLQ, NBN* and *PARP1* (rank 1 genes from Fig. 3A) across either BLBC or HGSOC cell lines. *TOPBP1* and *NBN* had higher co-dependence with CIP2A in BLBC than in HGSOC cells, while in HGSOC, *RHNO1* was more co-dependent with *CIP2A* (Fig. 3F). These differences may provide one plausible explanation for the differential requirement of *Cip2a* for DMBA-induced BLBC-like, but not ovarian cancer initiation (Fig. 1C, and S1B). Notably, *TOPBP1* did not show *CIP2A* co-dependence in HGSOC cells, but was co-dependent in BLBC cells (Fig. 3F).

CIP2A dampens TopBP1-RAD51 function under DNA damage

Although the results above identify a potential novel role for CIP2A in TopBP1-complex mediated G2/M arrest, there is currently no evidence for a direct mechanistic link between CIP2A and TopBP1. Here, by using a genome-wide Y2H assay with a human breast cancer cDNA library, TopBP1 was identified with very high confidence as an interaction partner for CIP2A (Fig. 4A) (Table S5). As Y2H assay only detects direct interactions between two proteins, we conclude that the CIP2A-TopBP1 association does not involve PP2A. However, as indicated by NBN phosphorylation data (38)(Fig. S3B), CIP2A may still protect proteins in the TopBP1 complex from PP2A-mediated dephosphorylation.

CIP2A is predominantly a cytoplasmic protein, but based on our current (Fig. S2B) and previous data (34), there is also a nuclear CIP2A pool in propagating cells *in vitro* and *in vivo*. Interaction between TopBP1 and endogenous nuclear CIP2A was confirmed from propagating cells by co-immunoprecipitation and proximity ligation analysis (Fig. 4B and S5A). γH2AX also co-immunoprecipitated with TopBP1 and CIP2A from DNAse treated cellular lysates indicating that direct TopBP1-CIP2A interaction occurs at chromatin (Fig.

4B). By narrowing down the minimal shared region between TopBP1 fragments interacting with CIP2A in the Y2H assay, the interaction with CIP2A was delineated to be mediated by the stretch of amino acids 829-853 located between 5th and 6th BRCT domain of TopBP1 (Fig. 4A, Table S5). The region between the 5th and 6th BRCT domain was also essential for interaction by co-immunoprecipitation analysis (Fig. 4C,D). Notably, the interaction was greatly strengthened by the presence of the ATR-activation domain (AAD) of TopBP1 adjacent to 6th BRCT repeat (Fig. 4C,D). As, no other DNA repair related proteins were identified in CIP2A Y2H screen (Table S5), the results support a model where direct binding to the scaffold protein TopBP1 mediates CIP2A interaction with the DDR network.

Directly linking CIP2A to TopBP1-regulated DDR, CIP2A inhibition significantly increased ATR phosphorylation in the propagating premalignant mammary cell line MCF-10A (Fig. 4E), and the highest phosphorylation of the ATR target H2AX (γH2AX)(41) was observed in CIP2A-depleted cells overexpressing AAD variant of TopBP1 (Fig. 4F). The role of CIP2A in dampening IR-induced γH2AX was validated in primary mammary epithelial cells isolated from WT and Cip2a-/- mice (Fig. S5B). Although PP2A has been validated as a γH2AX phosphatase in replication stressed cells (42), we interpret that increased γH2AX phosphorylation in CIP2A depleted replicating cells is rather due to increased TopBP1-associated ATR activity (7,8,41). Further supporting the role of CIP2A in dampening TopBP1 function, CIP2A depletion in IR-treated proliferating cells resulted in significantly enhanced chromatin recruitment of TopBP1 (Fig. 4G,H). This was specific to TopBP1, as CIP2A did not impact IR-induced p53BP1 chromatin recruitment (Fig. S5C). As CIP2A depletion did not induce ATM phosphorylation (Fig. S5D) which is a known mechanism increasing TopBP1 chromatin recruitment (8), we postulate that CIP2A prevents TopBP1 chromatin binding by direct interaction with its BRCT-domains (Fig. 4A). In BRCA wild-type

cells TopBP1 mediates G2/M arrest in response to IR by promoting RAD51 chromatin loading (10-12,43). Consistent with the G2/M arrest phenotype (Fig. 1E and 2D), and increased TopBP1 foci formation (Fig. 4G,H), the *Cip2a-/-* mammary epithelial cells exposed to IR displayed significantly enhanced RAD51 chromatin recruitment 2 hours after irradiation (Fig. 4I,J). Importantly, increased RAD51 retention at chromatin was observed still 6 hours after irradiation in *Cip2a-/-* mammary epithelial cells, indicating for a long-term defect in DNA repair foci clearance (Fig. S5E).

Together with the established role for TopBP1/RAD51 complex in DNA damage-induced G2/M checkpoint activity (7,9-11,43), the discovered CIP2A-mediated inhibition of TopBP1 and RAD51 chromatin recruitment provides a mechanism for dampening of the G2/M checkpoint in CIP2A-positive premalignant mammary epithelial cells (Fig. 4K).

CIP2A is essential for survival of TP53/BRCA-mutant BLBC cells

Next, we assessed whether the role of CIP2A as a mouse BLBC driver candidate translates to human BLBC. Firstly, both *CIP2A* and *TOPBP1* mRNA was found to be highest expressed in BLBC across the human breast cancer subtypes (Fig. 5A and S6A,B). *TP53* mutations in BLBC may result in activation of *CIP2A* gene promoter activity through the p21-E2F1 pathway (19) and accordingly, a significant correlation between *TP53* mutation, and high *CIP2A* expression was confirmed in the GSE21653 cohort (Fig. S6C). The clinical relevance and selectivity of CIP2A for human BLBC was evident from patient survival analysis. Both high mRNA and protein expression of CIP2A predicted poor disease-free and overall survival only in BL-TNBC, but not in non-BL-TNBC breast cancers (Fig. 5B-E, and S6D-H). CIP2A neither had a predictive role among patients with ER-

positive tumors, or in unselected breast cancers (Fig. S6D,G). Notably, the 5-year survival of patients with highly CIP2A positive BL-TNBC tumor was only about 50% in both patient cohorts (Fig. 5B, D), indicating that these high CIP2A tumors are particularly aggressive. Furthermore, high CIP2A expression significantly associated with mutation load in TNBC tumors based on TCGA data (Fig. S6I). This finding indicates that while CIP2A expression is not impacting mutation frequency per se (Fig. 1B), it allows survival of DNA-damaged cells (Fig. 1F), and thereby accumulation of tumor mutational load in fully developed TNBCs.

To assess the BLBC cell dependence on *CIP2A*, we surveyed the Dep-Map essentiality database across 33 breast cancer cell lines. Among the 12 cell lines with CERES gene dependency score less than -0.4 for *CIP2A* loss, the great majority of cell lines were found to be BLBC cells (Fig. 5F, Table S6). Notably, all except one of these most *CIP2A*-dependent BLBC cells carried either a *BRCA1* or *BRCA2* mutation which is a hallmark of BLBCs (Fig. 5F). Furthermore, in a genetically defined CRISPR/Cas9 model, *Cip2a* was found to be essential for colony growth of mouse mammary tumor cells depleted for *Trp53* and *Brca1* (*KB1P*; basal-type)(24)(Fig. 5G). However, *Cip2a* was dispensable for growth of either *Trp53/E-cadherin* mutant mammary tumor cells (*KEP*; invasive lobular carcinoma-type)(25)(Fig. 5G), or cells from the mice with activated AKT and loss of E-cadherin in mammary tumor cells (*WEA*; invasive lobular carcinoma-type)(26)(Fig. S7A). Furthermore, RNA-sequencing analysis from the most *CIP2A*-dependent *TP53*-mutant BLBC cell line (Fig. 5H, S7B) and HCC38 (*TP53 mutant/BRCA1 promoter methylation/BRCA2* mutant), revealed that CIP2A drove similar BLBC and HRD-associated gene expression programs as was observed from DMBA-treated mouse mammary tissue (Fig. 2D and Fig. 5I). The role of CIP2A in inhibiting the dephosphorylation of the activating phosphorylation sites in

449 both MYC and E2F1 was confirmed by western blot analyses (Fig. 5J). Finally, consistent
450 with recent identification of CIP2A as an essential gene in PARP inhibitor talazoparib-
451 treated cells (40), CIP2A depletion hypersensitized BRCA-proficient MDA-MB-231 cells to
452 two different PARP inhibitors (Fig. S7C).
453
454 These data reveal essentiality of CIP2A for the survival BRCA-deficient BLBC cells, and
455 thus fully support the mouse data indicating the driver role of CIP2A in BLBC. Clinically the
456 data introduces CIP2A as a potential biomarker to identify BL-TNBC patients with
457 particularly aggressive disease.
458
459
460 **Transcriptional CIP2A targeting by SMAPs as potential BLBC therapy**
461
462 Effective treatment of BLBCs represents a significant unmet medical need. As our data
463 indicate that CIP2A regulates PP2A activity towards both the TopBP1 complex (Fig. 3C
464 and S3B), as well as towards MYC and E2F1 (Fig. 5J), we tested whether a recently
465 developed series of Small Molecule Activators of PP2A (SMAPs) (14,16), could be used to
466 target CIP2A-expressing BLBC. SMAPs activate the CIP2A-regulated PP2A-B56alpha
467 heterotrimer (14,44), and the cellular effects of SMAPs in cancer cells are both correlated
468 with PP2A reactivation capacity, and can be rescued by concomitant PP2A inhibition
469 (22,45).
470
471 Treatment with two independent SMAPs (DBK-1154 and DT-061) resulted in a robust
472 inhibition of cell viability in eight established BL-TNBC cell lines (Fig. 6A and S8A), and in
473 five BLBC patient-derived cancer stem cell-like lines (27)(Fig. 6B). Notably, consistent with
474 notion that these cell lines were derived from tumors of patients that had undergone
475 neoadjuvant chemotherapy, these CIP2A positive (Fig. S8B) patient-derived BLBC cell

476 lines showed resistance to classical chemotherapies (Fig. 6B). Directly supportive of the
477 therapeutic relevance of these observations, oral DT-061 therapy resulted in significant
478 inhibition of tumor growth of an orthotopic PDX model from a patient with *TP53* mutant,
479 EGFR+ BLBC over a 40-day treatment period (Fig. 6C). Similar to other *in vivo* studies
480 with SMAPs (14,46,47), we did not observe any treatment-related adverse effects in mice.
481 Importantly the control tumors were CIP2A positive, whereas tumors from DT-061 treated
482 mice showed a clear trend for reduced CIP2A protein levels (Fig. S8C,D).
483
484 Related to a potential link between SMAP response and CIP2A, western blot analyses
485 revealed a surprising inhibition of CIP2A protein expression by SMAPs at 24 hours (Fig.
486 6D,E and S8E-G). Indicative of transcriptional level regulation, CIP2A protein inhibition
487 was accompanied with inhibition of *CIP2A* mRNA expression (Fig. 6F and S8G). The
488 candidate mechanism for SMAP-elicited *CIP2A* inhibition was evaluated by studying the
489 time course of CIP2A inhibition in relation to its two known upstream activators ERK and
490 MYC (20,21,33), which both are inhibited by SMAPs (45). Whereas inhibition of ERK
491 phosphorylation by SMAP preceded inhibition of CIP2A expression, MYC was inhibited in
492 SMAP treated cells after CIP2A inhibition (Fig. 6G, and S8H).
493
494 SMAPs, representing surrogate CIP2A inhibitors, were next tested for possible effects on
495 biomarkers of CIP2A activity. Consistent with results in CIP2A-depleted cells (Fig. 4),
496 SMAPs induced potent checkpoint signaling exemplified by phosphorylation of H2AX, ATR
497 and CHK2 (Fig. 6H,I and S9A,B). SMAP treatment for 24 hours also resulted in potent
498 inhibition of MYC protein expression (Fig. S9C). Regarding causality between SMAP-
499 induced checkpoint activation and CIP2A inhibition, SMAP-elicited CHK2 phosphorylation
500 preceded CIP2A inhibition (Fig. S9D,F), whereas the ToPBP1-related p-ATR and γH2AX

induction occurred only after CIP2A protein inhibition (Fig. 6J and S9D,E,G-H). Importantly, exogenous overexpression of CIP2A in MCF-10A cells, that were used to link the results to G2/M arrest (Fig. 1E), and TopBP1 effects (Fig. 4G,H), abrogated SMAP-elicited γH2AX induction (Fig. 6K and S9I). CIP2A overexpression also shifted the SMAP IC50 response in these cells (Fig. 6L). These results reveal that SMAPs have bi-phasic therapeutic activity consisting of direct PP2A activation (14,16), followed by transcriptional inhibition of *CIP2A* expression discovered here. SMAP-elicited CIP2A inhibition may thus halt the growth of BLBC cells by both prolonging the PP2A reactivation effects, but also via removing direct CIP2A-mediated direct effects on TopBP1 (Fig. 7).

Discussion

In this study, we provide comprehensive evidence that CIP2A overexpression can be a driver mechanism for BLBC initiation and malignant progression (Fig. 7). Consistent with the notion that even saturated genetic analysis of human breast cancers has failed to identify genetic BLBC driver, *CIP2A* gene sequence is not altered in BLBCs (https://cancer.sanger.ac.uk/cosmic). Instead, *CIP2A* expression is enhanced due to constitutive DNA-PK/CHK1 activity (48), TP53 inactivation (19), and EGFR pathway activation (20); which are all molecular hallmarks of BLBC (1,3)(Fig. *7*). Transcriptional *CIP2A* induction early in DMBA-induced tumorigenesis is also fully supportive of its role in BLBC tumor initiation. Together these findings provide an explanation for high *CIP2A* expression in BLBC, whereas its newly discovered interaction with TopBP1 forms a molecular basis for its essential function in allowing malignant progression of DNA-damaged mammary epithelial cells towards BLBCs.

As opposed to previous assumptions that CIP2A is involved in the development of multiple human solid cancers (17), our results demonstrate selective involvement of CIP2A in initiation and progression of BLBCs both in human and mice. In addition to *in vivo* tumorigenesis results, in genetically defined cell culture models, only the *Brca1/Trp53* mutant basal-like cells were dependent on *Cip2a* for their colony growth. Also in human breast cancer samples, high CIP2A expression predicted for poor patient survival exclusively in BLBCs. The selectivity of CIP2A for BLBCs among the tumor types studied here, can be molecularly explained by the notion that CIP2A is able to coordinate BLBC hallmarks via promoting proliferative MYC and E2F1 activities, and at the same time blunting the G2/M checkpoint via its effects on the TopBP1/RAD51 complex (Fig. 7). In

addition to TopBP1, other highly CIP2A co-dependent DDR genes (Fig. 3A), not studied in this work, might confer its BLBC selectivity. One such candidate gene is POLQ (Fig. 3A, S4A,B), that is upregulated, and promotes genetic instability in BL-TNBC cells (49).

The functional homology of CIP2A with a number of critical DNA damage proteins (Fig. 3A), is likely one of the most important contributions of this work for the future studies. This is supported by the recent results demonstrating essentiality of CIP2A in different DDR-related genomic screens (40,50). Here we focused on validation of the novel interaction between nuclear CIP2A and TopBP1. Based on our results, TopBP1 can induce effective DDR in CIP2A deficient cells, whereas in CIP2A positive cells the TopBP1/RAD51 complex chromatin recruitment is dampened allowing for continued mitotic activity (Fig. 4K). This mechanism is fully in line with previous data related to TopBP1-mediated G2/M checkpoint regulation (5,7,9,11,43). As a notion, we validated the CIP2A function in TopBP1/RAD51 complex and in G2/M checkpoint activity in BRCA-proficient cells (Fig. 1E, 4E-J, S5B-E). Whether the same mechanism is behind essentiality of CIP2A for HRD cells, including BRCA-deficient BLBC cells, remains to be studied. Importantly, in our model the enhanced TopBP1/RAD51 chromatin recruitment is due to loss of a direct and PP2A-independent CIP2A-TopBP1 interaction (Fig. 7). On the other hand, CIP2A can protect proteins in the TopBP1-associated complex from PP2A-mediated dephosphorylation as indicated with NBN S432 phosphorylation data (38). In addition, similar to other models (19,33,35), CIP2A inhibited dephosphorylation of both MYC and E2F1 in BLBC cells. CIP2A expression is in turn driven by MYC and E2F1 (19,33), and we postulate that these positive feedback loops have critical role in maintaining high proliferative activity in BLBC. Collectively, we conclude that CIP2A-mediated BLBC

562 initiation and progression results from a mixture of its PP2A-dependent and -independent
563 effects (Fig. 7).
564
565 In addition to identifying CIP2A as a driver candidate for BLBC, we demonstrate that
566 SMAPs (14) function as transcriptional inhibitors of *CIP2A* expression. Our results reveal a
567 model where SMAPs initially directly activate PP2A-B56 (14,16), and this followed by a
568 prolonged PP2A activation due to transcriptional downregulation of *CIP2A*. Importantly, we
569 were also able to demonstrate that CIP2A overexpression rescued the effects of SMAPs
570 as assessed by both decreases in cell viability and γH2AX regulation. However, it is
571 important to note that we consider SMAPs as surrogate CIP2A inhibitors that also have
572 acute effects not mediated by CIP2A inhibition, thereby explaining the anti-cancer effects
573 of SMAPs noted in other cancer types (46,47). Importantly, we validated the therapeutic
574 effects of three SMAPs across 15 different cell lines, including 6 individual patient-derived
575 lines and a PDX model, together minimizing concerns related to compound specific
576 effects, and known intratumoral heterogeneity of BLBC tumors.
577
578 Together these results credential CIP2A as a driver protein for one of the most aggressive
579 human cancer types, BLBCs. We also discover a novel link between CIP2A and DDR via
580 direct interaction with TopBP1. Generally, these results emphasize the importance in
581 characterizing proteome level signaling dysregulation in the cancer subtypes for which
582 genetic drivers are lacking.
583

584 **Acknowledgements**

585

586 We thank Taina Kalevo-Mattila for excellent technical assistance. Erica Nyman is thanked
587 for help in IHC analysis. Professor Wojciech Niedzwiedz and Dr. Andrew Blackford are
588 thanked for sharing research tools and protocols. We are very grateful to Ruth Keri Lab
589 from Case Western Reserve University for sharing the PDX model. Dr. Michael Ohlmeyer
590 (Atux Iskay LLC) is acknowledged for DBK-1154 and DBK-1160. Professor Johanna
591 Ivaska and Dipanjan Chowdhury are acknowledged for their valuable comments to the
592 data. We acknowledge Finnish Functional Genomics Center, Cell Imaging and Cytometry
593 core facility, and Genome Editing Core at Turku Bioscience Centre, and Turku Centre for
594 Disease Modeling (TCDM) all supported by Biocenter Finland, and/or ELIXIR Finland. The
595 Central Laboratory Animal Facilities of University of Turku are acknowledged for help with
596 the mouse models.

597 The project was funded by Academy of Finland (323096 for EP and 296801,
598 314443 and 310561 for LE), Finnish Cancer Foundations (JW), Finnish Cultural
599 Foundation (LE), Sigrid Juselius Foundation (JW, LE), Breast Cancer Now (JW, KW), and
600 Governmental Research Funding for Turku University Hospital (TG). DCC is supported by
601 the Fox Chase Cancer Center FCCC Core Grant NCI P30 CA006927. GN is supported by
602 R01 CA181654, HL144741, CA240993, W81XWH-19-BCRP-BTA12 DOD and Rogel
603 Cancer Gift Funds. JM is supported by Deutsche Forschungsgemeinschaft (DFG, German
604 Research Foundation; PN(407869199)). AL was supported by Oncode Institute, Svenska
605 Kulturfonden, Orion Research Foundation, Relander Foundation, Inkeri and Mauri
606 Vänskä's Foundation, Finnish Cultural Foundation's Varsinais-Suomi Regional Fund and
607 by K. Albin Johanssons Stiftelse. SN was supported by the the University of Turku

Graduate School (UTUGS), Instrumentarium Science Foundation and Ida Montin Foundation.

References:

1. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet **2017**;389:2430-42
2. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol **2008**;26:2568-81
3. Duijf PHG, Nanayakkara D, Nones K, Srihari S, Kalimutho M, Khanna KK. Mechanisms of Genomic Instability in Breast Cancer. Trends in molecular medicine **2019**;25:595-611
4. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y*, et al.* Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest **2011**;121:2750-67
5. Giunta S, Jackson SP. Give me a break, but not in mitosis: the mitotic DNA damage response marks DNA double-strand breaks with early signaling events. Cell Cycle **2011**;10:1215-21
6. Zheng XF, Kalev P, Chowdhury D. Emerging role of protein phosphatases changes the landscape of phospho-signaling in DNA damage response. DNA repair **2015**;32:58-65
7. Cotta-Ramusino C, McDonald ER, 3rd, Hurov K, Sowa ME, Harper JW, Elledge SJ. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science **2011**;332:1313-7

8. Sokka M, Parkkinen S, Pospiech H, Syvaoja JE. Function of TopBP1 in genome stability. Subcell Biochem **2010**;50:119-41

9. Kim WJ, Lee H, Park EJ, Park JK, Park SD. Gain- and loss-of-function of Rhp51, a Rad51 homolog in fission yeast, reveals dissimilarities in chromosome integrity. Nucleic Acids Res **2001**;29:1724-32

10. Liu Y, Smolka MB. TOPBP1 takes RADical command in recombinational DNA repair. J Cell Biol **2016**;212:263-6

11. Moudry P, Watanabe K, Wolanin KM, Bartkova J, Wassing IE, Watanabe S*, et al.* TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. J Cell Biol **2016**;212:281-8

12. Ogiwara H, Ui A, Onoda F, Tada S, Enomoto T, Seki M. Dpb11, the budding yeast homolog of TopBP1, functions with the checkpoint clamp in recombination repair. Nucleic Acids Res **2006**;34:3389-98

13. Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P*, et al.* Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature communications **2020**;11:2662

14. Leonard D, Huang W, Izadmehr S, O'Connor CM, Wiredja DD, Wang Z*, et al.* Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell **2020**;181:688-701

15. Kauko O, Westermarck J. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. Int J Biochem Cell Biol **2018**;96:157-64

16. Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases. Science translational medicine **2021**;13

17. Khanna A, Pimanda JE. Clinical significance of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in human cancers. Int J Cancer **2015**

18. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, *et al.* CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res **2009**;15:5092-100

19. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, *et al.* Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer discovery **2013**;3:182-97

20. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, *et al.* ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE **2011**;6:e17979

21. Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, *et al.* Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget **2015**;6:2164-79

22. Leonard D, Huang W, Izadmehr S, O'Connor CM, Wiredja DD, Wang Z, *et al.* Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell **2020**;181:688-701 e16

23. Kim S, Roopra A, Alexander CM. A phenotypic mouse model of basaloid breast tumors. PLoS One **2012**;7:e30979

24. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, *et al.* Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A **2007**;104:12111-6

25. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, *et al.* Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell **2006**;10:437-49

682 26. Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I*, et*
683 *al.* Loss of p53 triggers WNT-dependent systemic inflammation to drive breast
684 cancer metastasis. Nature **2019**;572:538-42
685 27. Metzger E, Stepputtis SS, Strietz J, Preca BT, Urban S, Willmann D*, et al.* KDM4
686 Inhibition Targets Breast Cancer Stem-like Cells. Cancer Res **2017**;77:5900-12
687 28. Ventelä S, Côme C, Mäkelä JA, Hobbs RM, Mannermaa L, Kallajoki M*, et al.* CIP2A
688 promotes proliferation of spermatogonial progenitor cells and spermatogenesis in
689 mice. PLoS ONE **2012**;7:e33209
690 29. Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E*, et al.* A Compendium
691 of Mutational Signatures of Environmental Agents. Cell **2019**;177:821-36 e16
692 30. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X*, et al.* Female
693 mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR
694 promoter develop epithelial ovarian cancer. Cancer Res **2003**;63:1389-97
695 31. Blomen VA, Majek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J*, et al.* Gene
696 essentiality and synthetic lethality in haploid human cells. Science **2015**;350:1092-6
697 32. Abba MC, Zhong Y, Lee J, Kil H, Lu Y, Takata Y*, et al.* DMBA induced mouse
698 mammary tumors display high incidence of activating Pik3caH1047 and loss of
699 function Pten mutations. Oncotarget **2016**;7:64289-99
700 33. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M*, et al.*
701 MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl
702 Cancer Inst **2009**;101:793-805
703 34. Myant K, Qiao X, Halonen T, Come C, Laine A, Janghorban M*, et al.* Serine 62-
704 Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A
705 Is Essential for Regenerative Proliferation. Cell reports **2015**;12:1019-31

35. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J*, et al.* Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci U S A **2014**;111:9157-62

36. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P*, et al.* CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene **2012**;31:4266-78

37. Oskarsson T, Essers MA, Dubois N, Offner S, Dubey C, Roger C*, et al.* Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev **2006**;20:2024-9

38. Kauko O, Imanishi SY, Kulesskiy E, Yetukuri L, Laajala TD, Sharma M*, et al.* Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. J Biol Chem **2020**;295:4194-211

39. Wohlbold L, Merrick KA, De S, Amat R, Kim JH, Larochelle S*, et al.* Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells. PLoS genetics **2012**;8:e1002935

40. DeWeirdt PC, Sangree AK, Hanna RE, Sanson KR, Hegde M, Strand C*, et al.* Genetic screens in isogenic mammalian cell lines without single cell cloning. Nature communications **2020**;11:752

41. Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol **2006**;26:6056-64

42. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell **2005**;20:801-9

43. Yamane K, Chen J, Kinsella TJ. Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint. Cancer Res **2003**;63:3049-53

44. Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T*, et al.* Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. EMBO reports **2017**;18:437-50

45. Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N*, et al.* Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest **2017**;127:2081-90

46. Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S*, et al.* PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science translational medicine **2018**;10

47. Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL*, et al.* Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. J Biol Chem **2020**;295:757-70

48. Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI*, et al.* Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. Cancer Research **2013**;73:6757-69

49. Prodhomme MK, Pommier RM, Franchet C, Fauvet F, Bergoglio V, Brousset P*, et al.* EMT transcription factor ZEB1 represses the mutagenic POLtheta-mediated end-joining pathway in breast cancers. Cancer Research **2020**;81:1595-606

50. Hustedt N, Alvarez-Quilon A, McEwan A, Yuan JY, Cho T, Koob L*, et al.* A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol **2019**;9:190156

Figure legends:

Figure 1. *Cip2a* knockout mice are selectively resistant to DMBA-induced mammary tumorigenesis. A, DMBA was orally administered to wild type (*WT*) and *Cip2a-/-* mice once a week for 6 consecutive weeks after which mice were monitored for signs of spontaneous tumor formation. **B,** Number of genetic variants in exons of the expressed genes in non-treated (control) and DMBA-treated *WT* (n=3) and *Cip2a-/-* (n=3) mouse mammary glands. P-value by Wilcoxon test. **C,** Incidences of tumor formation in different tissues in sacrificed DMBA-administered *WT* (n=18) and *Cip2a-/-* (n=14) mice. P-values between *WT* and *Cip2a-/-* groups calculated by Fisher's exact test. **D,** Incidence of mammary tumors in *WT* (n=18) and *Cip2a-/-* (n=14) mice after starting administration of DMBA. P-value by log-rank test. **E,** Mitotic index analysis of MCF10A cells transfected with the indicated siRNAs. Cells were treated with 10Gy radiation dose and Nocodazole (100 ng/ml) block 1 hour after IR for 18 hours. Mitotic cells were stained using phospho-histone H3 at Ser10. Scale bar: 100µm. Bar graph shows % of H3pS10 positive nuclei from three replicates, expressed as mean ± SD. **F,** Heat map of fraction of gene-trap insertions in the sense orientation compared to the total (sense and anti- sense) insertions in untreated HAP1 cells and HAP1 cells treated with successive low doses of IR (5x 1Gy). Color coding indicates essentiality of the indicated PP2A inhibitor protein for cell survival.

Figure 2: *Cip2a* drives initiation of mouse BLBC-like tumors A, qRT-PCR analysis of *Cip2a* mRNA expression normalized to *Actb* and *Gapdh* from *WT* and *Cip2a-/-* non-treated

(Ctrl) and DMBA-administered mouse non-tumorigenic mammary glands (MG), and from WT DMBA-induced mammary tumors. Shown is mean ± SD of 10 *WT* and 9 *Cip2a-/-* non-treated mammary glands (Ctrl MG), 3 *WT,* and 3 *Cip2a-/-* mammary glands from DMBA-administered mice, and 16 mammary tumors. P-values calculated by Mann-Whitney test. **B,** Representative images of immunohistochemical staining of Keratin-14 (K14), Keratin-8 (K8), CIP2A, Ki67 and MYC proteins and hematoxylin and eosin (HE) from DMBA-induced mammary tumors from *WT* mice. Scale bar: 50μM **C,** Semiquantitative analysis of receptor status from 10 WT tumors. **D,** Top five enriched hallmark gene sets based on differentially regulated genes in non-tumorigenic Cip2a KO mouse mammary glands treated with six doses of DMBA.

Figure 3: Co-dependence analysis reveals functional association of CIP2A with critical DNA damage response proteins A, Top 10 co-dependencies with *CIP2A* across 739 cell lines genome-wide from CRISPR Avana screen. *CIP2A*'s own co-dependency rank for the top 10 genes is also listed. Data extracted from DepMap portal (Avana 2020Q1). **B,** Genome-widely, *CIP2A* is the closest functional homologue to *RHNO1* and *TOPBP1*. **C,** STRING functional protein association network analysis of CIP2A co-dependent proteins from (A). By using the highest data confidence score (0.9), except for APEX2, DSCC1 and CIP2A, the other proteins form highly connected protein network. NBN phosphorylation indicated by red dot was found to be regulated by CIP2A based on (38). **D,** Top 10 Reactome pathways associated with genes from (A). **E,** Correlation between *CIP2A* and *TOPBP1* mRNA expression across 1156 cell lines from Cancer Cell Line Encyclopedia. **F,** Pair-wise correlation of dependence of either BLBC or HGSOC cell lines of the indicated genes from DepMap portal (Avana 2020Q1). The values for BLBC

and HGSOC indicates correlation (max. 1) in dependence of the cells for the genes in the gene pair; the higher number indicating for higher similarity in the dependence. The color-coded numbers indicate the difference in the co-dependence between BLBC and HGSOC cells for the indicated gene pair.

Figure 4: CIP2A is an interacting partner of TopBP1 and promotes mitotic progression of DNA damaged cells. A, Schematic presentation of breast cancer cell line cDNA fragments coding for TopBP1 domains that interact with full length CIP2A in a yeast two-hybrid assay. Numbers in the TopBP1 drawing refer to BRCT domains 1-8; AAD, ATR activation domain. Analysis of the minimal common overlapping region between the TopBP1 fragments interacting with CIP2A reveal the TopBP1 aa. 829-853 as a candidate CIP2A interaction domain. **B,** Co-immunoprecipitation of endogenous CIP2A and γH2AX in HEK293 cells transiently overexpressing GFP or full length TopBP1-GFP as indicated. Input 5% of total IP. **C,** Co-immunoprecipitation of CIP2A in HEK293 cells transiently overexpressing V5-tagged CIP2A and GFP-tagged Empty vector (EV) or TopBP1 truncated mutants T0, T1, T2, T3 as indicated in (D). Input 5% of total IP. **D,** Schematic representation of TopBP1 mutants used in (B,C) Relative interaction efficiencies are estimated from the experiment where all indicated mutants were included. **E,** Immortalized MCF10A cells transfected with non-targeting (*SCR*) or *CIP2A* siRNAs for 48hrs. Immunoblot of whole cell extracts (WCEs) probed for pATR, total ATR and CIP2A. Vinculin was used as a loading control. Relative quantifications of pATR/ATR and CIP2A plotted as Mean± SD from five replicates. **F,** MDA-MB-231 cells transfected with non-targeting (*SCR*) and *CIP2A* targeting siRNAs for 72 hrs and overexpressing TopBP1 mutants T0 and T1 as indicated for 48 hours. Immunoblot of WCEs probed for pATR, γH2AX and CIP2A. Actin

was used as a loading control. Relative quantifications of ɣH2AX plotted as Mean± SD from two replicates. **G,** IR-induced TopBP1 foci formation in MCF10A cells transfected with *SCR* or *CIP2A* siRNA as indicated for 48 hrs. Cells were treated with 5Gy radiation for 1 hour and stained for CIP2A or TopBP1. **H,** Quantifications of the nuclear foci from (G) expressed as mean ± SD from representative experiment of three experiments with similar results **I,** IR-induced RAD51 foci formation in mouse mammary epithelial cells (MMECs) isolated from *WT* and *Cip2a-/-* mice cultured *in-vitro* for 48 hrs, treated with 5Gy radiation for 2 hours. **J,** Quantifications of the foci in expressed as mean ± SD of representative experiment. **G-J,** Images were taken at 63X on 3i spinning disk confocal and at least 150 cells quantified per each condition using speckle counter pipeline on Cell Profiler. Scale bar: 10μM. **E-J,** All statistical analyses were conducted with Welch's Student t-test for unequal variances, *p<0.05, ** p<0.01 **K,** Schematic presentation of the role of CIP2A in directly inhibiting TopBP1/RAD51-elicited G2/M checkpoint activation in non-transformed mammary epithelial cells.

Figure 5: CIP2A is essential for survival of TP53/BRCA-mutant BLBC cells and drives proliferative signaling A, Expression of *CIP2A* mRNA in indicated molecular breast cancer subtypes. Data derived from TCGA. P-values by unpaired t-test. **B,** Disease-free survival of *CIP2A* high (n=15) and *CIP2A* low (n=45) expressing basal-like TNBC patients in GSE21653 cohort. **C,** Disease-free survival of *CIP2A* high (n=45) and *CIP2A* low (n=132) expressing non-basal-like (HER2+, luminal A, luminal B and normal-like) breast cancer patients in GSE21653 cohort. **D,** Overall survival of CIP2A high (n=12) and CIP2A low (n=51) basal-like TNBC patients in FinHer cohort. **E,** Overall survival of CIP2A high (n=17) and CIP2A low (n=47) non-basal like TNBC patients based IHC analysis from FinHer cohort. **B-E,** P-values calculated by log-rank test. **F,** *CIP2A*

dependence of breast cancer cell lines with CERES score < -0.4 from DepMap portal (Avana 2020Q1). Lower CERES scores indicate that the cell line is more dependent on *CIP2A*. Color coding indicates the breast cancer subtype of the cell line based on PAM50 classification. **G,** Colony growth assays conducted on mammary tumor cell lines isolated from basal-type (*KB1P#1* and *KB1P#2*: *Brca1* and *Trp53* mutant) and invasive lobular carcinoma (ILC)-type (*KEP#1* and *KEP#2*: *E-Cadherin* and *Trp53* mutant) mouse models; *Cip2a* was knocked out using CRISPR/Cas9 using 2 unique gRNAs. Western blots from the same samples probed for CIP2A below. Shown are representative images of at least 2 independent biological repeats for each cell line. **H,** Summary of *CIP2A*-dependence on colony growth of indicated *TP53*-mutant TNBC cell lines transfected with Mock, non-targeting siRNA (*siSCR*), or three unique *CIP2A* targeting siRNAs (*siCIP2A #1, #2, #3*). Colony areas were quantified and normalized to *siSCR*. **I,** Gene Set Enrichment Analysis (GSEA) conducted on differentially expressed genes obtained from RNA-seq of HCC38 cells depleted with 3 unique *CIP2A* siRNAs. **J,** HCC38 cells transfected with *SCR* or *CIP2A* siRNAs for 72 hrs and immunoblotted for indicated protein.

Figure 6: CIP2A targeting by SMAPs as potential BLBC therapy A, SMAP (DBK-1154) sensitivity profiles of eight BL-TNBC cell lines. Cell viabilities were measured using CellTiterGlo Luminescence Assay after 24 hrs of drug treatment. EC50s are listed in parentheses. **B,** Screening of patient-derived BLBC stem cell like cells for chemotherapy and SMAP responses. Heatmap indicates the drug sensitivity scores (DSS) of these cells across standard chemotherapeutics and three SMAPs DBK-1154, DT-061, NZ-1160). Higher DSS value indicates higher sensitivity. **C,** Tumor growth of an orthotopic patient derived xenograft model of basal triple negative breast cancer treated with DMA or 5mpk BID SMAP DT-061 for 43 days. Respective quantifications are represented as mean ± SD.

878 **D,E,** CIP2A western blots from MDA-MB-468 (D) and patient-derived stem cell-like cells,
879 BCSC1 (E) on treatment with indicated SMAPs for 24h. DT-061 and DBK-1154
880 concentration 20 µM. **F,** Kinetics of *CIP2A* mRNA expression from MDA-MB-468 cells after
881 treatment with 20uM of DT-061. n=3 expressed as mean ± SD. **G,** Kinetics of pT202/Y204-
882 ERK, CIP2A and pS62-MYC from MDA-MB-468 cell line treated with SMAP DT-061
883 (20uM) for indicated time points. Representative western blot data shown in Fig. S8H. n=3
884 expressed as mean ± SD. **H,** Quantification of Western blots of MDA-MB-468 cell line
885 treated with 20µM SMAP DT-061 for 24 hrs and probed for ɣH2AX, represented as mean
886 ± SD from n=3 replicates normalized to the untreated controls**. I,** Quantification of western
887 blots from MDA-MB-468 cell line treated with 20uM of DT-061 for 24hrs, displayed in Fig.
888 S9A. Data expressed as mean ± SD from n=3 replicates normalized to the untreated
889 controls. **J,** Time course of CIP2A and ɣH2AX protein expression in MDA-MB-468 treated
890 with DT-061 (20 µM) for indicated time periods. Western blot data are shown in Fig. S8F
891 and S9B. **K,** CIP2A overexpression in MCF10A cell line rescues the SMAP-elicited ɣH2AX
892 activation. Western blots of parental and CIP2A OE MCF10A cells treated with SMAP
893 DBK-1154 for 24hrs and probed for ɣH2AX. GAPDH is used as loading control; ɣH2AX
894 quantifications from n=4 replicates displayed below. **L,** Dose response curve of control and
895 CIP2A OE stable cell line (CIP2A OE) MCF10A cells on treatment with concentration
896 series of DBK-1154 for 24 hours. IC50 values indicated in parenthesis. **A-L,** p-values
897 calculated using unpaired t-test, *P<0.05, **P<0.01, *** P<0.001, ****P<0.0001.
898
899 **Figure 7. Schematic presentation of the role for CIP2A in coordinating BLBC**
900 **molecular hallmarks**. The capacity of CIP2A to co-ordinately regulate G2/M checkpoint,
901 and proliferative signaling by MYC and E2F1, provides a molecular basis for its role as
902 BLBC driver. Black arrows indicate known mechanisms implicated in BLBC that either

regulate CIP2A expression and/or promote BLBC progression. Green arrows indicate PP2A inhibition-dependent mechanisms by which CIP2A increase proliferation capacity of BLBC cells. The PP2A-dependence of these mechanisms has been demonstrated previously (19,36). The orange block arrow indicates direct binding of CIP2A to TopBP1 and inhibition of TopBP1-mediated checkpoint activity in response to DSB in premaligant mammary epithelial cells. Green block arrow indicates potential PP2A-dependent regulation of NBN phosphorylation. Collectively, CIP2A both responds to hallmarks of BLBCs (p53 inhibition, EGFR activity and HR defects) and co-ordinately controls the essential functional hallmarks; G2/M checkpoint and high proliferation activity. The relationship between CIP2A and BLBC hallmarks is also a plausible explanation for the selective role for CIP2A in BLBC as compared to other cancer types.





C

	WT (n=18)	*Cip2a-/-* (n=14)	p-value
Mammary tumor	44.44%	7.14%	0.0443
Ovary and fal. tubes tumor	61.11%	64.29%	>0.9999
Lung tumor	50.00%	35.71%	0.4896
Skin papillomas	27.78%	28.57%	>0.9999
Stomach wall tumor	22.22%	21.43%	>0.9999
Tumor with unknown origin	5.56%	7.14%	>0.9999
Splenomegaly	72.22%	35.71%	0.0720
Liver abnormality	38.89%	21.43%	0.4461
Lymphadenopathy	27.78%	21.43%	>0.9999
Thymus hyperplasia	22.22%	21.43%	>0.9999
Pancreas abnormality	16.67%	21.43%	>0.9999
Intestine abnormality	5.56%	7.14%	>0.9999
Appendicitis	5.56%	0.00%	>0.9999







Figure 1

A



B



C

Receptor status of WT mammary tumors

Tumor	ER	PR	HER2
#1	-	-/+	-
#2	-	-	-
#3	-/+	+	-
#4	-	-/+	-
#5	-	-	-
#6	+	+	-
#7	+	+	-
#8	-	+	-
#9	-	-	-
#10	-	-	-

D

RNASeq: non tumorigenic *Cip2a* KO vs WT mouse MGs

Top 5 Hallmark gene sets enriched in genes downregulated in Cip2a KO

GENE SET NAME	NES	FDR q-value
HALLMARK_OXIDATIVE_PHOSPHORYLATION	-3.071	0
HALLMARK_E2F_TARGETS	-2.928	0
HALLMARK_MYC_TARGETS_V1	-2.840	0
HALLMARK_G2M_CHECKPOINT	-2.605	0
HALLMARK_MYC_TARGETS_V2	-2.527	0

Figure 2

Author Manuscript Published OnlineFirst on June 18, 2021; DOI: 10.1158/0008-5472.CAN-20-3651
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

A

CRISPR Avana 2020 Q1 data from Depmap

CIP2A co-dependent genes

	Gene	Dependency correlation	*CIP2A*'s association rank with the gene
1.	*RHNO1*	0.486	1
2.	*H2AX*	0.402	3
3.	*TOPBP1*	0.392	1
4.	*MDC1*	0.339	4
5.	*POLQ*	0.327	1
6.	*NBN*	0.315	1
7.	*XRCC1*	0.302	2
8.	*APEX2*	0.295	2
9.	*PARP1*	0.294	1
10.	*DSCC1*	0.280	7

B

RHNO1 co-dependent genes

	Gene	Dependency correlation
1.	*CIP2A*	0.49
2.	*H2AX*	0.34
3.	*RNF168*	0.32
4.	*TOPBP1*	0.31
5.	*MDC1*	0.31

TOPBP1 co-dependent genes

	Gene	Dependency correlation
1.	*CIP2A*	0.39
2.	*RAD17*	0.31
3.	*RHNO1*	0.31
4.	*MDC1*	0.27
5.	*ATR*	0.27

C

STRING analysis; highest confidence score (0.9)



D

Reactome pathways associated with *CIP2A* co-dependent genes

Pathway	Description	FDR
HSA-5693538	Homology Directed Repair	4.44E-14
HSA-5685939	HDR through MMEJ (alt-NHEJ)	1.47E-09
HSA-69473	G2/M DNA damage checkpoint	1.20E-08
HSA-5693607	Processing of DNA double-strand break ends	1.20E-08
HSA-5685938	HDR through Single Strand Annealing (SSA)	1.30E-05
HSA-5693616	Presynaptic phase of homologous DNA pairing and strand exchange	1.38E-05
HSA-5693571	Nonhomologous End-Joining (NHEJ)	2.86E-05
HSA-5693565	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	3.82E-05
HSA-212436	Generic Transcription Pathway	7.47E-05
HSA-6804756	Regulation of TP53 Activity through Phosphorylation	1.00E-04

E



F

	BLBC	HGSOC	BLBC-HGSOC
CIP2A vs. *TOPBP1*	0,263	-0,141	0,404
CIP2A vs. *NBN*	0,819	0,510	0,309
CIP2A vs. *POLQ*	0,507	0,520	-0,013
CIP2A vs. *PARP1*	0,378	0,422	-0,043
CIP2A vs. *RHNO1*	0,195	0,699	-0,504

BLBC co-dependent — HGSOC co-dependent

Figure 3



Figure 4



Figure 5



Figure 6



Figure 7

AACR American Association for Cancer Research

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis

Anni Laine, Srikar G. Nagelli, Caroline Farrington, et al.

Cancer Res Published OnlineFirst June 18, 2021.